How should sumatriptan be used for acute treatment of moderate to severe migraine in adults without cardiovascular disease, including dosing, routes, contraindications, and alternatives?

Sumatriptan for Acute Migraine Treatment

For adults with moderate-to-severe migraine without cardiovascular disease, sumatriptan should be used in combination with an NSAID (such as ibuprofen or naproxen) as first-line therapy, initiated as early as possible after symptom onset. 1

Dosing and Routes of Administration

Oral Sumatriptan (Most Common Route)

• Standard dosing: 25 mg, 50 mg, or 100 mg as a single dose 2
• The 50 mg oral dose is most commonly prescribed, achieving pain-free response in approximately 28% of patients at 2 hours (vs. 11% with placebo; NNT 6.1) 1
• Maximum daily dose: 200 mg in 24 hours 2
• Redosing: A second dose may be considered only if some response to the first dose was observed, separated by at least 2 hours 2
• Hepatic impairment: Maximum single dose should not exceed 50 mg in patients with mild-to-moderate hepatic impairment; contraindicated in severe hepatic impairment 2

Alternative Routes for Specific Situations

• Subcutaneous (4 mg or 6 mg): Most effective route with pain-free response in 59% at 2 hours (NNT 2.3), providing more rapid relief than oral administration 3, 4
• Consider subcutaneous or intranasal formulations with an antiemetic in patients experiencing severe nausea or vomiting 1
• Intranasal (5 mg, 10 mg, 20 mg) and rectal (25 mg) formulations are available but less commonly used 3

Treatment Algorithm

Step 1: Initial Therapy

• First-line for moderate-to-severe migraine: Triptan (sumatriptan) + NSAID (ibuprofen, naproxen, aspirin, diclofenac, or celecoxib) 1
• Initiate treatment as early as possible after migraine onset to improve efficacy 1
• For mild migraine: Start with NSAID alone, acetaminophen alone, or NSAID + acetaminophen before escalating to triptans 1

Step 2: If Inadequate Response

• Ensure adequate dosing of both the NSAID and triptan before declaring treatment failure 1
• Try a different triptan within the class, as patients who fail one triptan may respond to another (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, zolmitriptan) 1
• Consider alternative routes of sumatriptan administration (subcutaneous, intranasal) 3

Step 3: Second-Line Alternatives

• CGRP antagonists (gepants): Rimegepant, ubrogepant, or zavegepant for patients who fail or cannot tolerate triptan + NSAID combination 1, 5
• Dihydroergotamine (ergot alkaloid): Alternative rescue medication when first-line agents are ineffective 5
• Lasmiditan (ditan): Reserved for patients who have exhausted all other acute therapeutic options 1, 5

Absolute Contraindications

Sumatriptan is contraindicated in the following conditions: 2

• History of coronary artery disease or coronary artery vasospasm
• Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders
• History of stroke, transient ischemic attack, hemiplegic or basilar migraine
• Peripheral vascular disease
• Ischemic bowel disease
• Uncontrolled hypertension
• Recent (within 24 hours) use of another 5-HT₁ agonist (another triptan) or ergotamine-containing medication
• Concurrent or recent (past 2 weeks) use of monoamine oxidase-A inhibitor
• Hypersensitivity to sumatriptan (angioedema and anaphylaxis reported)
• Severe hepatic impairment

Critical Safety Considerations

Cardiovascular Risk Assessment

• Perform cardiac evaluation in patients with multiple cardiovascular risk factors before initiating sumatriptan 2
• Recent evidence suggests increased cardiovascular risk: Patients with cardiovascular disease or elevated cardiovascular risk who use triptans have a 4-fold increased risk of major adverse cardiovascular events (MACE) at 60 days (RR 4.00), though absolute incidence remains low (1.48% vs. 0.37%) 6
• Case reports document sumatriptan-induced coronary vasospasm leading to acute ST-elevation myocardial infarction, even in patients with non-obstructive coronaries 7
• In patients with cardiovascular disease, CGRP antagonists (gepants) are preferred alternatives to triptans 5

Medication Overuse Headache

• Threshold for medication overuse headache with triptans: ≥10 days per month 1
• Counsel patients about this risk and consider preventive migraine therapy if attacks are frequent 1

Serotonin Syndrome Risk

• Use with caution in patients taking SSRIs or other serotonergic medications due to potential for serotonin syndrome 2
• Discontinue sumatriptan immediately if serotonin syndrome occurs 2

Common Adverse Events

• Most common (≥2%): Paresthesia, warm/cold sensation, chest pain/tightness/pressure, neck/throat/jaw pain/tightness/pressure, vertigo, malaise/fatigue 2
• Adverse events are generally mild, transient, and more common with higher doses 3, 8
• Chest/throat/neck/jaw symptoms are generally not associated with myocardial ischemia, but evaluate for coronary artery disease in high-risk patients 2

Special Populations

Pregnancy and Lactation

• Acetaminophen is the safest acute migraine medication in pregnancy 5
• NSAIDs may be used before the third trimester 5
• Sumatriptan can be considered when anticipated benefit outweighs potential risk, though it may cause fetal harm based on animal data 5, 2
• Discuss adverse effects during pregnancy and lactation with patients of childbearing potential 1

Patients with Cardiovascular Disease

• Triptans should be avoided entirely 5
• CGRP antagonists (gepants) are the preferred alternative 5

What NOT to Use

Do not use opioids or butalbital-containing products for acute episodic migraine treatment. 1, 5 These medications are strongly associated with medication overuse headache (threshold ≥10 days/month for butalbital) and progression to chronic migraine 5.